Efficacy of Adjuvant Chemotherapy Using Oral Fluorinated Pyrimidines for Curatively Resected Gastric Cancer: A Meta-Analysis of Centrally Randomized Controlled Clinical Trials in Japan

Abstract Adjuvant chemotherapy for gastric cancer has been extensively explored in Japan since the 1950s, and a combination of oral fluorinated pyrimidines (o-FP) and mitomycin C (MMC) has been mainly utilized for adjuvant chemotherapy. However, there is no sufficient evidence for the efficacy of adjuvant therapy. Therefore, we assessed the efficacy of o-FPs over surgery alone (control) by means of a meta-analysis of Japanese centrally randomized controlled clinical trials conducted between 1980 and 2005. For inclusion in this study, studies had to compare adjuvant chemotherapy for curatively resected gastric cancer with surgery alone, mainly targeting o-FP, and central randomization designed to comply with contemporary standards for clinical trials in Japan. For the 4 trials that met the eligibility criteria, the estimated hazard ratio was 0.73 (95%CI = 0.60-0.89). Our findings show that in Japan adjuvant chemotherapy using o-FP for long-term maintenance therapy appears to be effective for gastric cancer patients after curative resection.

[1]  K. Inokuchi.  Prolonged survival of gastric cancer patients on a specific adjuvant chemotherapy , 1984, The Japanese journal of surgery.

[2]  Tsuneo Sasaki.  [In regard to gastric cancer treatment guidelines--a revised edition]. , 2004, Gan to kagaku ryoho. Cancer & chemotherapy.

[3]  Y. Kodera,et al.  Adjuvant chemotherapy for gastric cancer in Japan: global and Japanese perspectives , 2004, Cancer Chemotherapy and Pharmacology.

[4]  J. Macdonald.  Clinical overview: adjuvant therapy of gastrointestinal cancer , 2004, Cancer Chemotherapy and Pharmacology.

[5]  D. Thamm,et al.  Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma , 2004, Cancer Chemotherapy and Pharmacology.

[6]  A. Nashimoto,et al.  Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. M. Parkin,et al.  Corrigendum to “Cancer burden in the year 2000. The global picture” [European Journal of Cancer,37(Suppl. 8) (2001) S4–S66] , 2003 .

[8]  Aller,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2002, The New England journal of medicine.

[9]  Y. Maehara,et al.  Adjuvant chemotherapy for gastric cancer: a comprehensive review , 2001, Gastric Cancer.

[10]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[11]  F. Bray,et al.  Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.

[12]  H. Katai,et al.  [Current status and problem of adjuvant chemotherapy for curatively resected gastric cancer]. , 2000, Gan to kagaku ryoho. Cancer & chemotherapy.

[13]  H. Nagawa,et al.  [Interim report on JFMTC Study no. 21 on the effectiveness of UFT as an adjuvant therapy for semi-advanced cancer of the stomach]. , 2000, Gan to kagaku ryoho. Cancer & chemotherapy.

[14]  A. Nashimoto,et al.  Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial , 1999, The Lancet.

[15]  Y. Nio,et al.  Second malignancies after a gastrectomy for gastric cancers: the effects of adjuvant therapies. , 1999, Anticancer research.

[16]  C. Earle,et al.  Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. , 1999, European journal of cancer.

[17]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[18]  S. Watanabe,et al.  [Preoperative adjuvant chemotherapy with oral anticancer agents for stomach cancer]. , 1997, Gan to kagaku ryoho. Cancer & chemotherapy.

[19]  P. Fayers,et al.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial , 1996, The Lancet.

[20]  S. Romano,et al.  Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. , 1996, British Journal of Cancer.

[21]  R. Hanka.  The Handbook of Research Synthesis , 1994 .

[22]  T. Nakajima,et al.  [Meta-analysis of 10 postoperative adjuvant chemotherapies for gastric cancer in CIH]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[23]  M. Fujii,et al.  [The optimal period for orally administered fluoropyrimidines as an adjuvant chemotherapy for gastric cancer--a pilot study using 5-FU tablets compared with surgical operation alone]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[24]  Ingram Olkin,et al.  Stochastically dependent effect sizes. , 1994 .

[25]  O. Abe,et al.  [Study of pre- and post-operative chemotherapy with oral 5-FU in patients with gastric cancer. Study Group of Pre- and Post-Operative Oral 5-FU in Gastric Cancer]. , 1993, Gan to kagaku ryoho. Cancer & chemotherapy.

[26]  K. Takasaki,et al.  [An evaluation of perioperative and continuous infusion of tegafur as surgical adjuvant chemotherapy of resected gastric cancer]. , 1992, Gan to kagaku ryoho. Cancer & chemotherapy.

[27]  T. Watanabe,et al.  [Postoperative adjuvant chemotherapy using NCS (neocarzinostatin) and 5-FU in the treatment of gastric cancer. First report--A comparison with the 5-year survival rate of patients undergoing combined therapy with MMC and 5-FU]. , 1987, Gan to kagaku ryoho. Cancer & chemotherapy.

[28]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[29]  T. Nakajima,et al.  Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Pera,et al.  Mitomycin C as an Adjuvant in Resected Gastric Cancer , 1983, Annals of surgery.

[31]  H. Yamagishi,et al.  [Evaluation of postoperative long-term chemotherapy using FT-207 for the stage III stomach cancer]. , 1982, Gan to kagaku ryoho. Cancer & chemotherapy.